These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8628282)

  • 1. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
    Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.
    Durick K; Gill GN; Taylor SS
    Mol Cell Biol; 1998 Apr; 18(4):2298-308. PubMed ID: 9528800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
    Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
    Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain.
    Durick K; Wu RY; Gill GN; Taylor SS
    J Biol Chem; 1996 May; 271(22):12691-4. PubMed ID: 8662982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Shc docking site on Ret tyrosine kinase.
    Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
    Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
    Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
    Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities.
    Liu X; Vega QC; Decker RA; Pandey A; Worby CA; Dixon JE
    J Biol Chem; 1996 Mar; 271(10):5309-12. PubMed ID: 8621380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
    Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
    Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
    Asai N; Iwashita T; Matsuyama M; Takahashi M
    Mol Cell Biol; 1995 Mar; 15(3):1613-9. PubMed ID: 7532281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.